Most popular posts
- What makes great boards great
- The fate of control
- March Madness and the availability heuristic
- When business promotes honesty
- Due diligence: mine, yours, and ours
- Alligator Alley and the Flagler (?!) Dolphins
- Untangling skill and luck in sports
- The Southeastern Growth Corridors
- Dead cats and iterative collaboration
- Empirical evidence: power corrupts?
- A startup culture poses unique ethical challenges
- Warren Buffett and after-tax returns
- Is the secret to national prosperity large corporations or start-ups?
- This is the disclosure gap worrying the SEC?
- "We challenged the dogma, and it was incorrect"
- Our column in the Tampa Bay Business Journal
- Our letter in the Wall Street Journal
Other sites we recommend
Monthly Archives: September 2017
With a new CEO and additional equity financing to optimize wellness program delivery for small and midsize employers, MeYou Health is ready to become the first provider of a wellness software-as-a-service (SaaS) solution in the SMB market.
Boston, MA. (PRWEB) September 27, 2017
MeYou Health (MYH) today announced that Trapper Markelz, current President and Chief Operations Officer, has been named Chief Executive Officer of the Company. MYH has also secured additional equity financing from Ballast Point Ventures and other current investors to accelerate the Company’s efforts to optimize wellness program delivery for small and midsize employers. Both announcements are part of a major initiative by MYH to take its highly automated white-label platform for health plans and layer on a fully self-service customer interface to enable the Company to become the first provider of a wellness software-as-a-service (SaaS) solution in the SMB market.
Mr. Markelz, 40, began his career at MYH in 2009 as Head of Product, and in 2015 assumed the role of General Manager. He was named President and Chief Operating Officer in 2016 after MeYou Health was spun out from its former parent company, and he has been instrumental in building and scaling sales operations, account management, implementation, B2B marketing, and automated digital enrollment marketing.
Matt Rice, a partner with Ballast Point Ventures and Chairman of the MYH Board of Directors, says, “Trapper is the ideal person to lead the talented team at MeYou Health, as his vision, judgment, and leadership have been crucial to the Company’s success over the years. MYH’s move into the HR SaaS market has momentum, and we are excited to fund additional growth.”
“I’m very excited by this opportunity and see it as a great honor to lead this Company,” says Mr. Markelz. “Over the last eight years, our team has learned enormously from our work with hundreds of employers, both large and small. MeYou Health has always been a software company, and now we can use that software expertise to deliver a market-leading, fully automated solution.”
MeYou Health provides a full-feature, turn-key wellness suite optimized for small and midsize businesses. Designed for digital delivery, MeYou Health’s platform was built from the ground up to give employers a social, engaging, and effective alternative to traditional wellness programming. With industry-leading engagement and multiple clinical trials demonstrating impact, MeYou Health’s programs deliver measurable results to even the smallest organization. Founded in 2009 and based in Boston, MA, MeYou Health is made up of talented people from healthcare, engineering, design, and research backgrounds, all dedicated to helping employers improve their employees’ health and well-being.
PORTLAND, Ore. and CAMBRIDGE, Mass., Sept. 28, 2017 (GLOBE NEWSWIRE) — MolecularMD, a provider of molecular and tissue-based clinical trial assays and diagnostics for oncology based drug development programs, has announced a partnership agreement with Indica Labs, a leader in digital pathology imaging tools and services.
The collaboration between the companies leverages MolecularMD’s diagnostic clinical testing solutions with Indica Labs’ digital biomarker analysis services to enable an efficient transition of pre-clinical research to the diagnostic setting and deployment of advanced image analysis workflows. Mindful that many of its clients are using Indica Labs’ products and services, MolecularMD envisions the partnership will facilitate seamless transition of image analysis methods to the clinical trial setting for accelerated drug development programs.
“Indica Labs’ HALOTM image analysis software and the HALO LinkTM image management system provides advanced image analysis capabilities in a global collaborative environment,” said Doug Bowman, Vice President of Pharma Services at Indica Labs. “This agreement will allow our clients to take advantage of MolecularMD’s capabilities, and MolecularMD’s clients to develop quantitative assays to better understand biomarker expression levels and spatial relationships relative to the tissue microenvironment.”
“The agreement will provide our clients with integrated genomic and phenotypic biomarker analyses that are crucial for accurate and effective patient stratification,” said Dan Snyder, President and Chief Executive Officer at MolecularMD.
“Indica Labs fills our clients’ needs for digital biomarker analysis and enhances our proposition to immuno-oncology development programs. These capabilities will provide unique advantages and accelerate pipeline decisions. The use of advanced algorithms for IHC data interpretation holds the possibility of improved patient outcomes,” said Snyder.
Indica Labs will attend the Pathology Visions 2017 Conference; which brings together the luminaries and key opinion leaders in digital pathology. More information about the partnership can be found at the Indica Labs Booth #7. Pathology Visions 2017 will be held from October 1-3, 2017 in San Diego at the Manchester Grand Hyatt. For more information about Pathology Visions 2017, click here.
MolecularMD Corporation develops and commercializes specialty molecular diagnostics for oncology applications. Its tests are designed to allow appropriate selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. MolecularMD integrates gold standard and innovative platform technologies with custom clinical assay design and validation to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. A private company based in Portland, Oregon, MolecularMD was founded by Dr. Brian Druker, director of the Knight Cancer Institute at Oregon Health & Science University, and Sheridan G. Snyder, entrepreneur and founder of Genzyme Corporation. Learn more at www.molecularmd.com
Fritz Eibel, SVP and Chief Marketing Officer
About Indica Labs
Indica Labs is the first company to offer tissue specific and application specific image analysis algorithms in a truly integrated digital pathology environment. Pharmaceutical, healthcare, and research organizations worldwide utilize Indica tools for high-throughput, whole-slide image quantification in areas such as neuroscience, metabolism, oncology, toxicological pathology, and more. Learn more at www.indicalab.com
Douglas Bowman, VP of Pharma Services